Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026377 · ClinicalTrials.gov registry record · Phase 1
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00026377 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 3 participants.
The verdict
NCT00026377, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, bicalutamide, leuprolide, or goserelin may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining SU5416, hormone therapy, and radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 plus hormone therapy and radiation therapy in treating patients who have prostate cancer.
Interventions
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG bicalutamide
- DRUG flutamide
- DRUG SU5416
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2001-11 |
| Est. Completion | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026377
The ClinicalTrials.gov registry entry for NCT00026377 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which leuprolide acetate is the first listed.
NCT00026377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026377 about?
NCT00026377 is a clinical study titled "SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, bicalutamide, leuprolide, or goserelin may fight prostate cancer by reducing the production of androgens. Radiation thera...
What is the current status of trial NCT00026377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2001-11. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00026377?
The interventions under investigation include: leuprolide acetate (DRUG), goserelin acetate (DRUG), bicalutamide (DRUG), flutamide (DRUG), SU5416 (DRUG).
Who is sponsoring clinical trial NCT00026377?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.